In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jumpstarting Research: Big Pharma's Out-Licensing Dilemma

Executive Summary

At Windhover's Jumpstart to Products Conference, a number of speakers, including Merck's head of basic research, argued--at least by implication--that Big Pharma needs to do more of the kinds of reformulations and re-indications of existing compounds that net them products faster and with less risk--that allow them to "jumpstart" R&D. For biotechs pursuing a similar strategy, getting starter material--in the form of compounds Pharma has abandoned--is crucial, though few Pharmas are willing to out-license. Lilly is the great exception to this rule: the company's Joe Zakrzewski argues why outlicensing is critical to his firm's success.
Advertisement

Related Content

Finding a Way Out of Pharma's Dealmaking Dilemma
Finding a Way Out of Pharma's Dealmaking Dilemma
The Anti-Global, Specialist Strategy: Why Bayer's Choice Might Be Right for Other Pharmas
The Anti-Global, Specialist Strategy: Why Bayer's Choice Might Be Right for Other Pharmas
Novartis Out, Merck In, a Win for Vertex's Aurora Kinase Program
Novartis Out, Merck In, a Win for Vertex's Aurora Kinase Program
Jumpstart to Products
Jumpstart to Products
In-Licensing: Still a Difficult Model

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002304

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel